In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech's Euro-Marketing Gambit

Executive Summary

Europe presents a big opportunity--but also significant challenges--to niche players seeking to expand. Some firms--such as US group Cephalon--have bought big in Europe, others like Shire and Celltech have made do with smaller acquisitions onto which they hope to build their own tailored infrastructure. No single approach is the same, and none has yet proven a clear winner. But all depend on finding the right products.
Advertisement

Related Content

Pharmion's Euro Bet Pays Off
Pharmion's Euro Bet Pays Off
Ex-Shire Team Builds New Euro-Specialty Group
Ex-Shire Team Builds New Euro-Specialty Group
Europe's Flavors of Sustainable BioPharma
Europe's Flavors of Sustainable BioPharma
Strakan: Refining Search & Development
Pharmion Bets that Europe is Alright for Some
Pharmion Bets That Europe is Alright for Some
Cephalon Learns That Risk Returns

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel